A new clinical trial has shown promising results for patients suffering from both chronic kidney disease (CKD) and type 2 diabetes. The study, funded by Bayer and registered under ClinicalTrials.gov number NCT05254002, found that initial combination therapy with finerenone and empagliflozin significantly reduced the urinary albumin-to-creatinine ratio (UACR), a key marker of kidney damage, more effectively than either treatment used alone.
Finerenone is a non-steroidal mineralocorticoid receptor antagonist, while empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor. Both drugs have shown individual benefits in reducing risks associated with CKD and type 2 diabetes. The CONFIDENCE trial brings these two therapies together to evaluate whether combined treatment yields superior renal outcomes.
Participants in the study, all diagnosed with both CKD and type 2 diabetes, were randomly assigned to receive either the combination of both medications or monotherapy with one of the agents. The primary outcome measured was the reduction in UACR, which serves as an indicator of kidney function and a predictor of disease progression.
Results demonstrated that patients receiving the combination therapy experienced a more pronounced decrease in UACR levels compared to those receiving only one of the medications. This indicates a potentially synergistic effect when both drugs are administered together, offering enhanced renal protection in a population at high risk for kidney failure and cardiovascular complications.
These findings suggest that a dual-therapy approach could become a more effective strategy for managing CKD in patients with type 2 diabetes. Further long-term studies are needed to confirm these benefits and determine implications for clinical practice and patient outcomes.
Source: https:// – Courtesy of the original publisher.
